Stock listing

NYSE:NUVB Nuvation Bio Inc. Stock

Home listing (NYSE) of Nuvation Bio Inc.

Follow Nuvation Bio Inc. into a list and get an email when it puts out news.

Share price · NYSE:NUVB

$3.80 USD +0.02 (+0.5%)

Close on Nov 20, 2026

Past year -45.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.72 – $3.91 USDNov 20, 2026
Volume
6.85M sharesNov 20, 2026
Market cap
$1.34B USDAt the close on Nov 20, 2026 · price × 353.0M shares outstanding
52-week range
$3.72 – $9.75 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$27.18M USDMedian day 4.84M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Nuvation Bio Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:NUVB · Home$3.80 USD+0.02 (+0.5%)6,848,938$3.77$3.91$3.72$3.78Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:NUVB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.80+0.02+0.5%$3.77$3.91$3.726,848,938
$3.78-0.12-3.1%$3.92$3.975$3.775,956,075
$3.90+0.06+1.6%$3.80$3.98$3.7885,752,952
$3.84-0.15-3.8%$3.99$4.00$3.827,826,513
$3.99-0.07-1.7%$4.03$4.115$3.9453,086,620
$4.06-0.23-5.4%$4.22$4.22$4.035,614,021
$4.29+0.09+2.1%$4.27$4.375$4.222,951,650
$4.20-0.15-3.4%$4.23$4.355$4.113,478,343
$4.35+0.19+4.6%$4.23$4.43$4.0755,326,427
$4.16-0.03-0.7%$4.21$4.329$3.985,328,011
$4.19-0.54-11.4%$4.459$4.81$4.188,419,216
$4.73+0.04+0.9%$4.70$4.75$4.528,369,789
$4.69+0.10+2.2%$4.62$4.785$4.615,141,344
$4.59-0.17-3.6%$4.80$4.85$4.593,723,263
$4.76-0.01-0.2%$4.75$4.805$4.605,059,887
$4.77+0.18+3.9%$4.65$4.835$4.646,495,901
$4.59+0.04+0.9%$4.48$4.60$4.4255,213,784
$4.55+0.04+0.9%$4.51$4.59$4.365,042,823
$4.51-0.06-1.3%$4.62$4.68$4.483,660,066
$4.57-0.13-2.8%$4.62$4.66$4.443,190,400
$4.70-0.15-3.1%$4.83$4.91$4.6555,805,100
$4.85+0.08+1.7%$4.77$4.96$4.724,501,300
$4.77+0.29+6.5%$4.51$4.82$4.466,853,000
$4.48+0.03+0.7%$4.48$4.60$4.3454,222,000
$4.45-0.30-6.3%$4.75$4.76$4.424,471,300
$4.75+0.07+1.5%$4.74$4.855$4.674,822,800
$4.68-0.04-0.8%$4.66$4.80$4.613,779,000
$4.72-0.18-3.7%$4.86$4.92$4.717,607,800
$4.90-0.10-2.0%$4.96$5.005$4.883,182,900
$5.00+0.05+1.0%$4.95$5.06$4.872,957,000
$4.95+0.09+1.9%$4.80$4.98$4.6259,289,800
$4.86-0.02-0.4%$4.81$4.95$4.795,448,700
$4.88-0.07-1.4%$4.96$4.97$4.736,653,200
$4.95-0.19-3.7%$5.12$5.16$4.859,963,000
$5.14-0.42-7.6%$5.66$5.66$5.0314,825,000
$5.56-0.04-0.7%$5.57$5.616$5.4523,471,200
$5.60-0.02-0.4%$5.81$5.825$5.595,547,000
$5.62+0.02+0.4%$5.59$5.69$5.543,068,000
$5.60-0.14-2.4%$5.68$5.68$5.484,584,700
$5.74+0.01+0.2%$5.73$5.825$5.672,816,600
$5.73+0.02+0.4%$5.69$5.78$5.5355,705,600
$5.71-0.39-6.4%$6.07$6.07$5.694,603,900
$6.10+0.03+0.5%$6.26$6.26$5.9554,323,000
$6.07+0.22+3.8%$6.00$6.105$5.863,026,200
$5.85-0.22-3.6%$6.15$6.18$5.824,433,900
$6.07+0.29+5.0%$5.96$6.16$5.925,738,500
$5.78-0.02-0.3%$5.80$5.82$5.6552,781,200
$5.80-0.14-2.4%$5.90$5.91$5.637,051,900
$5.94-0.13-2.1%$5.90$6.135$5.7710,029,800
$6.07-0.21-3.3%$6.36$6.39$5.954,318,000
$6.28-0.24-3.7%$6.44$6.45$6.177,979,800
$6.52-0.09-1.4%$6.55$6.715$6.502,611,400
$6.61-0.20-2.9%$6.69$6.746$6.582,541,900
$6.81+0.04+0.6%$6.78$6.87$6.723,755,200
$6.77-0.16-2.3%$7.03$7.13$6.655,266,900
$6.93+0.29+4.4%$6.75$6.97$6.694,996,700
$6.64-0.02-0.3%$6.60$6.95$6.584,843,600
$6.660.000.0%$6.695$6.753$6.4853,199,800
$6.66-0.33-4.7%$6.90$6.996$6.6253,662,000
$6.99+0.03+0.4%$6.91$7.18$6.883,530,300
$6.96-0.14-2.0%$7.09$7.12$6.913,439,000
$7.10+0.34+5.0%$6.93$7.13$6.8554,154,798
$6.76-0.17-2.5%$6.82$6.97$6.663,015,226
$6.93+0.10+1.5%$6.98$7.09$6.886,035,800
$6.83-0.43-5.9%$7.31$7.31$6.765,312,500
Ticker
NYSE:NUVB
Asset type
Stock
Exchange
NYSE
Currency
USD

What changed lately

Latest news

All Nuvation Bio Inc. news

Nuvation Bio Inc. on 6ix

News releases
36 in the last 12 months · 58 in all · newest Nov 16, 2026 · oldest 2025
Calls
6 calls with a replay · 6 with a transcript · latest Nov 4, 2026
Decks
20 decks · latest Aug 6, 2026

Where Nuvation Bio Inc. is listed

ListingExchangeCountryCurrency
NYSE:NUVB · Home listing · This pageNYSEUnited StatesUSD
BOATS:NUVBBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$963.5M USD
P/E
Loss
EV/sales
4.8×
EV/EBITDA
Negative EBITDA
Price/book
5.9×
Gross margin
90.6%
Operating margin
−61.2%
Net margin
−67.4%
Debt to equity
1.3×
Beta vs S&P 500
1.49

Forecasts

9 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
12.45 USD · Analysts' mean
EPS, year to Dec 2026
-0.29 · 2 analysts
Revenue, year to Dec 2026
203.2M · 13 analysts

Team and board

Officers

OfficerRole
David HungFounder, President and Chief Executive Officer
Philippe SauvageChief Financial Officer
Stephen DangChief Legal Officer
Eisai CoLtd. Investor Relations Department
Colleen SjogrenChief Commercial Officer
David HanleyChief Technical Operations Officer
Gary HattersleyChief Scientific Officer
Kerry WentworthChief Regulatory Officer
Stacy MarkelChief People Officer

Board

DirectorRole
David HungFounder, President and Chief Executive Officer
Junyuan Jerry WangBoard of Directors
Kathryn FalbergBoard of Directors
Kim D. BlickenstaffBoard of Directors
Min CuiBoard of Directors
Robert BazemoreLead Independent Director, Board of Directors
Robert MashalBoard of Directors
W. Anthony VernonBoard of Directors

Events

Calls

CallWhenStatus
Nuvation Bio (NYSE:NUVB) Q3 2026 Earnings CallWed, Nov 04, 2026 · 4:30 PM ETReplay
Nuvation Bio (NYSE:NUVB) Q2 2026 Earnings CallThu, Aug 06, 2026 · 8:00 AM ETReplay
Nuvation Bio (NYSE:NUVB) Q1 2026 Earnings CallMon, May 04, 2026 · 4:30 PM ETReplay
Nuvation Bio (NYSE:NUVB) Q3 2025 Earnings CallMon, Nov 03, 2025 · 4:30 PM ETReplay
Nuvation Bio (NYSE:NUVB) Q2 2025 Earnings CallThu, Aug 07, 2025 · 8:00 AM ETReplay
Nuvation Bio (NYSE:NUVB) Q1 2025 Earnings CallWed, May 07, 2025 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−11.4%
Q2 2026Aug 6, 2026 · Before open−4.1%
Q1 2026May 4, 2026 · After close+9.5%
Q4 2025Mar 2, 2026−26.2%
Q3 2025Nov 3, 2025 · After close−6.6%
Q2 2025Aug 7, 2025 · Before open−0.4%
Q1 2025May 7, 2025 · After close+2.9%
Q4 2024Feb 26, 2025 · Before open−3.4%
Q3 2024Nov 6, 2024 · After close+3.1%
Q2 2024Aug 5, 2024 · Before open−5.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close0.0%
Q4 2023Feb 29, 2024 · After close+19.3%
Q3 2023Nov 2, 2023 · After close+5.5%
Q2 2023Aug 3, 2023 · After close+4.5%
Q1 2023May 4, 2023 · After close+3.1%
Q4 2022Mar 15, 2023 · After close+2.4%
Q3 2022Nov 3, 2022 · After close−2.3%
Q2 2022Aug 4, 2022 · After close+5.1%
Q1 2022May 9, 2022 · After close+4.7%
Q4 2021Feb 28, 2022 · After close−3.4%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings34 slidesAug 6, 2026
Q1 2026 Earnings PresentationEarnings34 slidesMay 4, 2026
Investor Presentation (January 2026)Investor deck37 slidesJanuary 2026
Investor Presentation (November 2025)Investor deck36 slidesNov 26, 2025
Investor Presentation (November 2025)Investor deck39 slidesNov 17, 2025
Q2 2025 Earnings PresentationEarnings6 slidesAug 7, 2025
Q2 2025 Earnings PresentationEarnings38 slidesAug 7, 2025
Investor Presentation (June 2025)Investor deck37 slidesJun 11, 2025
Technical Presentation (May 2025)Technical10 slidesMay 7, 2025
TD Cowen 45th Annual Health Care Conference 2025Conference40 slidesMar 3, 2025
All 20 decks
DeckKindSlidesDate
43rd Annual J.P. Morgan Healthcare Conference (January 2025)Conference27 slidesJan 13, 2025
Investor Presentation (October 2024)Investor deck40 slidesOctober 2024
Merger or Acquisition (March 2024)Merger or acquisition14 slidesMar 25, 2024
Investor Presentation (November 2023)Investor deck28 slidesNovember 2023
Investor Presentation (August 2023)Investor deck28 slidesAugust 2023
Investor Presentation (December 2022)Investor deck33 slidesDec 23, 2022
Investor Presentation (January 2022)Investor deck55 slidesJan 10, 2022
Investor Presentation (March 2021)Investor deck54 slidesMarch 2021
Panacea Acquisition — SPAC Merger (January 2021)SPAC merger58 slidesJan 5, 2021
SPAC Merger (October 2020)SPAC merger47 slidesOct 21, 2020

Open Decks

Financings

RaiseDate
0.75% Convertible Senior Notes due 2032
Closed: US$287.5M raised
Use of proceeds: Pay about $2.2 million for additional capped call transactions; remainder for general corporate purposes including working capital and operating expenses
Jul 6, 2026
0.75% Convertible Senior Notes due 2032
Made bigger: US$250M · Jefferies LLC +3
Dealers: Jefferies LLC (co-lead), Citigroup (co-lead), Cantor Fitzgerald & Co. (co-lead), RBC Capital Markets, LLC
Use of proceeds: Pay for capped call transactions, repay in full its senior secured loan agreement, and general corporate purposes
Jun 26, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Panacea Acquisition Corp, a blank check company (SPAC). Priced at US$10.00 a unit on Jun 30, 2020.

Price
US$10.00 a unit
Units offered
12,500,000 units
Offering size
US$125 million
Underwriters' option
Up to 1,875,000 more units
Listing
PANA.U on the New York Stock Exchange
Underwriter
Cowen
Units delivered
On or about Jul 6, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceMay 15, 2020
Filed publiclyJun 12, 2020
Amended onceJun 23, 2020
Shares registered with an exchangeJun 26, 2020
Declared effective by the SECJun 30, 2020
Final prospectus, with the priceJul 2, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jul 2, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue62.9M7.87M0000
Cost of revenue8.44M7.08M0484.0K368.0K103.0K
Gross profit54.5M795.0K0-484.0K-368.0K-103.0K
Research and development115.1M99.1M71.3M87.8M69.0M32.6M25.1M482.7K
Selling, general and administrative151.6M69.2M28.5M31.9M24.3M10.9M6.59M509.3K
Operating income-213.1M-592.6M-99.8M-119.7M-93.3M-43.6M-32.1M-992.0K
Depreciation and amortization1.74M683.0K222.0K199.0K184.0K103.0K13.0K992.0K
EBITDA-211.3M-591.9M-99.6M-119.5M-93.1M-43.4M-32.1M0
Interest expense13.7M341.0K09.16M644.0K000
Income before tax-204.6M-567.9M-75.8M-104.2M-86.8M-41.7M-33.6M-992.0K
Income tax000000
Net income-204.6M-567.9M-75.8M-104.2M-86.8M-41.7M-33.6M-992.0K
Earnings per share, basic-0.60-2.11-0.35-0.48-0.44-0.43-0.16-0.01
Earnings per share, diluted-0.60-2.11-0.35-0.48-0.44-0.43

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents164.1M35.7M42.6M101.1M132.4M29.8M3.47M138.0K
Short-term investments365.1M467.0M568.6M559.9M633.0M186.0M115.4M
Receivables19.4M16.3M3.70M2.48M3.04M1.09M828.0K
Inventory11.4M0643.1M2.92M
Current assets571.5M526.3M616.4M667.3M772.1M220.7M119.9M158.0K
Property, plant and equipment564.0K586.0K717.0K894.0K786.0K688.0K646.0K
Total assets594.8M540.6M621.5M672.1M776.2M221.8M121.0M158.0K
Accounts payable9.48M6.35M2.21M2.14M3.92M2.17M2.03M83.0K
Current liabilities82.2M58.2M14.0M13.2M16.9M6.55M3.20M902.0K
Long-term debt47.2M
Total debt52.9M8.91M4.01M4.26M3.06M600.0K
Total liabilities289.1M76.8M16.4M17.1M30.2M6.71M3.20M902.0K
Shareholders' equity305.7M463.8M605.1M655.1M746.0M215.1M117.7M-744.0K
Shares outstanding346.5M337.8M219.0M218.6M217.9M149.0M206.7M183.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-173.4M-130.4M-68.0M-96.1M-68.2M-36.5M-24.4M-616.0K
Capital spending-354.0K-162.0K-69.0K-370.0K-282.0K-145.0K-659.0K-659.0K
Free cash flow-173.8M-130.6M-68.1M-96.5M-68.5M-36.7M-25.1M-616.0K
Cash from investing99.5M122.7M8.92M63.5M-454.7M-70.3M-115.9M-115.9M
Cash from financing202.5M331.0K628.0K1.33M625.5M133.1M143.6M800.0K
Share buybacks939.0K758.0K135.7M
Change in cash128.4M-6.93M-58.5M-31.3M102.7M26.3M3.33M184.0K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 4, 2026ResultsSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
8-K · Current reportAug 6, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
8-K · Current reportJul 6, 2026FinancingSEC
8-K · Current reportJun 30, 2026Material contractSEC
424B5 · ProspectusJun 26, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
305B2Jun 26, 2026Other filingsSEC
FWP · Free writing prospectusJun 26, 2026Offer documentSEC
424B5 · ProspectusJun 25, 2026Offer documentSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportMay 27, 2026Meeting outcomeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4/A · Change in ownership, amendedMay 26, 2026Insider tradeSEC
8-K · Current reportMay 4, 2026ResultsSEC
10-Q · Quarterly reportMay 4, 2026Quarterly reportSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 17, 2026Other filingsSEC
144 · Notice of proposed saleApr 17, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 10, 2026Annual reportSEC
DEF 14A · Proxy statementApr 10, 2026Meeting noticeSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
144 · Notice of proposed saleApr 6, 2026Other filingsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 3, 2026Offer documentSEC
10-K · Annual reportMar 2, 2026Annual reportSEC
8-K · Current reportMar 2, 2026ResultsSEC
25-NSEFeb 10, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 26, 2025Other filingsSEC
8-K · Current reportNov 26, 2025Current reportSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
8-K · Current reportNov 17, 2025Current reportSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
S-8 · Registration statement for employee plansNov 3, 2025Offer documentSEC
10-Q · Quarterly reportNov 3, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025ResultsSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
144 · Notice of proposed saleOct 27, 2025Other filingsSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Current reportSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
4 · Change in ownershipMay 6, 2025Insider tradeSEC
144 · Notice of proposed saleMay 2, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 28, 2025Big-stake noticeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 8, 2025Annual reportSEC
DEF 14A · Proxy statementApr 8, 2025Meeting noticeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
8-K · Current reportMar 25, 2025Material contractSEC
S-3ASR · Registration statementMar 6, 2025Offer documentSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
8-K · Current reportMar 5, 2025Material contractSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
8-K · Current reportMar 4, 2025Material contractSEC
8-K · Current reportFeb 12, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 6, 2024ResultsSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedOct 18, 2024Big-stake noticeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
4 · Change in ownershipOct 9, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 9, 2024Insider tradeSEC
8-K · Current reportOct 7, 2024Management or board changeSEC
SC 13D · Big-stake noticeSep 10, 2024Big-stake noticeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
8-K · Current reportSep 5, 2024Meeting outcomeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 16, 2024Other filingsSEC
424B3 · ProspectusAug 15, 2024Offer documentSEC
DEFR14AAug 13, 2024Meeting noticeSEC
CORRESP · Letter to the SECAug 12, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 8, 2024Other filingsSEC
S-3 · Registration statementAug 5, 2024Offer documentSEC
10-Q · Quarterly reportAug 5, 2024Quarterly reportSEC
8-K · Current reportAug 5, 2024ResultsSEC
ARS · Annual report to shareholdersJul 30, 2024Annual reportSEC
DEF 14A · Proxy statementJul 30, 2024Meeting noticeSEC
UPLOAD · Letter from the SECJul 16, 2024Other filingsSEC
CORRESP · Letter to the SECJul 16, 2024Other filingsSEC
PRER14AJul 16, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 12, 2024Other filingsSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
8-K/A · Current report, amendedJun 20, 2024Current reportSEC
CORRESP · Letter to the SECJun 18, 2024Other filingsSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
UPLOAD · Letter from the SECJun 10, 2024Other filingsSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
PRER14AMay 24, 2024Other filingsSEC
PRE 14A · Preliminary proxy statementMay 24, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-K/A · Annual report, amendedApr 26, 2024Annual reportSEC
S-8 · Registration statement for employee plansApr 18, 2024Offer documentSEC
4 · Change in ownershipApr 11, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 11, 2024Insider tradeSEC
4 · Change in ownershipApr 11, 2024Insider tradeSEC
4 · Change in ownershipApr 11, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 11, 2024Insider tradeSEC
8-K · Current reportApr 10, 2024Acquisition or disposalSEC
3 · Initial statement of ownershipApr 2, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMar 26, 2024Big-stake noticeSEC
8-K · Current reportMar 25, 2024Material contractSEC
S-8 · Registration statement for employee plansMar 4, 2024Offer documentSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
8-K · Current reportFeb 29, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJan 29, 2024Big-stake noticeSEC
4 · Change in ownershipJan 10, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 10, 2024Insider tradeSEC
8-K · Current reportJan 8, 2024Management or board changeSEC
8-K · Current reportDec 14, 2023Management or board changeSEC
3 · Initial statement of ownershipNov 27, 2023Insider tradeSEC
8-K · Current reportNov 27, 2023Management or board changeSEC
8-K · Current reportNov 13, 2023Management or board changeSEC
8-K · Current reportNov 2, 2023ResultsSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
4/A · Change in ownership, amendedSep 22, 2023Insider tradeSEC
4 · Change in ownershipSep 21, 2023Insider tradeSEC
10-Q · Quarterly reportAug 3, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023ResultsSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC

This page holds 200 of 400 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Nuvation Bio Inc.’s releases · as of Oct 30, 2026

Common shares
353,017,638
Fully diluted
353,017,638

Fully diluted

LineSharesAs of
Common shares353,017,638Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026353,017,638

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Fidelity52.7M14.9%US$295M+438KNov 10, 2026
BlackRock28.9M8.2%US$162M+1.29MNov 13, 2026
Decheng Capital LLC26M7.4%US$145MNo changeNov 13, 2026
Vanguard17.1M4.8%US$95.5M+254KNov 16, 2026
Laurion Capital Management LP7.7M2.2%US$43.1M−123KOct 30, 2026
State Street7.6M2.2%US$42.5M+225KNov 12, 2026
Omega Fund Management, LLC7.15M2.0%US$40M−930KNov 16, 2026
Geode Capital6.45M1.8%US$36.1M+202KNov 6, 2026
American Century4.52M1.3%US$25.3M+19,398Nov 20, 2026
Goldman Sachs4.51M1.3%US$25.3M+2.61MNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Jones Hill Capital LP4.49M1.3%US$25.1MNewNov 13, 2026
Two Sigma3.3M0.93%US$18.5M+2.05MNov 16, 2026
Tang Capital Management LLC3.3M0.93%US$18.5MNo changeNov 16, 2026
Redmile Group, LLC3.03M0.86%US$17MNo changeNov 16, 2026
Connor, Clark & Lunn Investment Management Ltd.2.54M0.72%US$14.2M+780KNov 10, 2026
AQR Capital Management LLC2.51M0.71%US$14M+152KNov 16, 2026
Jacobs Levy Equity Management, Inc2.46M0.70%US$13.8M+1.93MNov 16, 2026
Citadel2.37M0.67%US$13.3M+383KNov 16, 2026
Northern Trust2.34M0.66%US$13.1M+18,280Nov 16, 2026
Schwab2.3M0.65%US$12.9M+246KNov 16, 2026
Duquesne Family Office LLC2.27M0.64%US$12.7M−2.27MNov 16, 2026
Hrt Financial LP2.1M0.59%US$11.7M−111KNov 13, 2026
Armistice Capital, LLC2.1M0.59%US$11.7M+96,000Nov 16, 2026
Morgan Stanley2.08M0.59%US$11.6M+620KNov 13, 2026
Dimensional1.83M0.52%US$10.2M−223KNov 4, 2026
Franklin Templeton1.73M0.49%US$8.19M+1.61MNov 12, 2026
Knoll Capital Management, LLC1.6M0.45%US$8.95MNo changeNov 16, 2026
First Trust1.56M0.44%US$8.73M+257KNov 12, 2026
NewEdge Advisors, LLC1.55M0.44%US$8.66M+315KNov 13, 2026
BNP Paribas1.54M0.44%US$8.61M+1.49MNov 12, 2026
UBS1.39M0.39%US$7.8M−233KNov 16, 2026
Essex Investment Management Co LLC1.34M0.38%US$7.53M+674KOct 19, 2026
JPMorgan1.33M0.38%US$7.46M+813KNov 12, 2026
Nan Fung Group Holdings Ltd1.33M0.38%US$7.43MNewNov 13, 2026
Renaissance Technologies1.32M0.37%US$7.39M−26,300Nov 12, 2026
Invesco1.29M0.37%US$7.22M+702KNov 12, 2026
Bank of America1.27M0.36%US$7.13M−2.26MNov 16, 2026
Abrams Capital Management, L.P.1.27M0.36%US$7.11MNo changeNov 13, 2026
Woodline Partners LP1.24M0.35%US$6.92M+260KNov 16, 2026
Jump Financial, LLC1.24M0.35%US$6.92M−123KNov 13, 2026
Nuveen1.12M0.32%US$6.25M+32,298Nov 10, 2026
Silvercrest Asset Management Group LLC1.09M0.31%US$6.1M+67,221Nov 16, 2026
Squarepoint Ops LLC1.03M0.29%US$5.76M+864KNov 9, 2026
Wellington995K0.28%US$5.57M+280KNov 16, 2026
D. E. Shaw & Co., Inc.903K0.26%US$5.06M−237KNov 16, 2026
Millennium700K0.20%US$3.92M+327KNov 16, 2026
Man Group plc695K0.20%US$3.89M+285KNov 16, 2026
Barclays665K0.19%US$3.72M+433KNov 6, 2026
BNY663K0.19%US$3.71M−7,042Nov 5, 2026
ExodusPoint Capital Management, LP646K0.18%US$3.62M+579KNov 16, 2026

This page holds 50 of 251 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Growth Company Fund17.5M5.0%US$83.8M+603KMay 31, 2026
Vanguard Total Stock Market Index Fund8.85M2.5%US$50.3M+193KJun 30, 2026
iShares Russell 2000 ETF6.57M1.9%US$37.3M+670KJun 30, 2026
Fidelity Growth Company K6 Fund4.91M1.4%US$23.5M+106KMay 31, 2026
Fidelity Series Growth Company Fund4.52M1.3%US$21.6M+157KMay 31, 2026
Small Cap Growth Fund3.42M0.97%US$21.7M+1.24MJul 31, 2026
Vanguard Extended Market Index Fund2.79M0.79%US$15.8M+131KJun 30, 2026
Fidelity Small Cap Index Fund2.76M0.78%US$17.4M+371KJul 31, 2026
iShares Russell 2000 Growth ETF2.33M0.66%US$13.2M+2.16MJun 30, 2026
Select Biotechnology Portfolio1.76M0.50%US$8.41M−406KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
iShares Biotechnology ETF1.74M0.49%US$9.9M−52,496Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF1.43M0.40%US$8.11M+141KJun 30, 2026
Fidelity Extended Market Index Fund1.24M0.35%US$5.92M−14,905May 31, 2026
Vanguard Russell 2000 Index Fund1.24M0.35%US$5.92M+43,117May 31, 2026
Schwab U.S. Small-Cap ETF1.15M0.32%US$5.47M−16,509May 31, 2026
U.S. Micro Cap Portfolio956K0.27%US$6.05MNo changeJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund909K0.26%US$5.76M+108KJul 31, 2026
iShares Micro-Cap ETF844K0.24%US$4.8M+237KJun 30, 2026
BlackRock Advantage Small Cap Core Fund812K0.23%US$3.88M+55,228May 29, 2026
Vanguard Health Care Index Fund662K0.19%US$3.16M−5,614May 31, 2026
iShares U.S. Pharmaceuticals ETF634K0.18%US$3.6M−35,194Jun 30, 2026
Schwab Small-Cap Index Fund612K0.17%US$3.88M+84,366Jul 31, 2026
iShares Genomics Immunology and Healthcare ETF536K0.15%US$3.39M+110KJul 31, 2026
North Square Dynamic Small Cap Fund485K0.14%US$2.32M+345KMay 31, 2026
Tanaka Growth Fund485K0.14%US$2.32MNo changeMay 31, 2026
Master Small Cap Index Series471K0.13%US$2.68M+96,091Jun 30, 2026
First Trust Small Cap Core AlphaDEX Fund461K0.13%US$2.92M+138KJul 31, 2026
Fidelity Total Market Index Fund447K0.13%US$2.14MNo changeMay 31, 2026
Dimensional U.S. Small Cap ETF431K0.12%US$2.73M−6,633Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF406K0.11%US$2.57M−2,715Jul 31, 2026
Tema Oncology ETF395K0.11%US$1.89M+33,267May 31, 2026
Invesco Dorsey Wright Healthcare Momentum ETF395K0.11%US$2.5MNewJul 31, 2026
Fidelity Series Total Market Index Fund364K0.10%US$1.74M+2,912May 31, 2026
ALPS Medical Breakthroughs ETF357K0.10%US$1.71M+51,701May 31, 2026
Nuveen Small Cap Blend Index Fund333K0.09%US$2.11M+62,845Jul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF308K0.09%US$1.75M+7,344Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account307K0.09%US$1.75M+303KJun 30, 2026
Small Cap Equity Fund282K0.08%US$1.6MNewJun 30, 2026
Virtus Biotech Etf276K0.08%US$1.75M+164KJul 31, 2026
EQ/2000 Managed Volatility Portfolio274K0.08%US$1.55M+26,661Jun 30, 2026
JPMorgan Small Cap Value Fund266K0.08%US$1.51M−16,198Jun 30, 2026
Nuveen ESG Small-Cap ETF238K0.07%US$1.51MNewJul 31, 2026
Fidelity Small Cap Growth Index Fund236K0.07%US$1.34M+222KJun 30, 2026
Small Cap Growth Fund231K0.07%US$1.1MNewMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF221K0.06%US$1.4M−63,753Jul 31, 2026
Vanguard U.S. Momentum Factor ETF218K0.06%US$1.04M+140May 31, 2026
1290 Essex Small Cap Growth Fund214K0.06%US$1.36MNewJul 31, 2026
iShares ESG Aware MSCI USA Small-Cap ETF191K0.05%US$912K−29,640May 31, 2026
U.S. Small Cap Portfolio185K0.05%US$1.17MNo changeJul 31, 2026
LVIP State Street Small-Cap Index Fund179K0.05%US$1.02M+14,200Jun 30, 2026

This page holds 50 of 175 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Hattersley Gary
Officer: CHIEF SCIENTIFIC OFFICER
Sale100,000USD 7.09US$709KAug 19, 2026
Wentworth Kerry
Officer: CHIEF REGULATORY OFFICER
Sale63,000USD 6.02US$379KJun 23, 2026
Markel Stacy
Officer: CHIEF PEOPLE OFFICER
Sale125,000USD 6.03US$754KJun 23, 2026
Sauvage Philippe
Officer: Chief Financial Officer
Sale47,668USD 6.01US$286KJun 23, 2026
Mashal Robert
Director
Buy25,000USD 4.73US$118KJun 9, 2026
Wentworth Kerry
Officer: CHIEF REGULATORY OFFICER
Sale36,750USD 5.01US$184KApr 17, 2026
Liu Dongfang
Officer: CHIEF MEDICAL OFFICER
Sale50,000USD 5.02US$251KApr 17, 2026
Wentworth Kerry
Officer: CHIEF REGULATORY OFFICER
Sale200,000USD 4.52US$904KApr 6, 2026

Big stakes

HolderStakeSharesDate
FMR LLC15.00%50.6MMar 31, 2025
BlackRock, Inc.6.40%21.7MJun 30, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kathryn Falberg
Other companies: Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 24, 2016 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Jazz Pharmaceuticals plc (EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past)
Board of Directors · Since at least Feb 10, 2021
Daniel Bradbury
Other companies: Vivani Medical, Inc. (Member of the Board · Since at least Mar 4, 2024); Castle Biosciences, Inc. (Board Chairman · Since at least Jul 24, 2019); Equillium, Inc. (Chairman of the Board · Since at least Oct 11, 2018); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past); BioMed Realty Trust (Director · Jan 1, 2013 – Jan 27, 2016 · Past); Corcept Therapeutics Incorporated (Director · Oct 10, 2012 – Feb 7, 2019 · Past); Geron Corporation (Director · Sep 26, 2012 – Mar 29, 2019 · Past); Illumina, Inc. (Director · Jun 8, 2006 – May 25, 2017 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 13, 2008 · Past); Amylin Pharmaceuticals LLC (President & Chief Executive Of, Director · Jan 5, 2006 – Feb 22, 2012 · Past)
Director · Jun 30, 2020 – Feb 10, 2021 · Past
Faheem Hasnain
Other companies: Aspen Neuroscience, Inc. (Aspen Executive Chairman · Since at least Nov 2, 2026); Gossamer Bio, Inc. (Co-Founder, Chairman, and Chief Executive Officer · Since at least Feb 7, 2019); Kura Oncology, Inc. (Lead Independent Director · Since at least Apr 23, 2015); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Immunic, Inc. (Director · Aug 11, 2016 – Sep 13, 2018 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Nov 10, 2014 · Past); Receptos Inc (President & CEO, Director · May 8, 2013 – Aug 25, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Sep 16, 2010 – Dec 31, 2012 · Past); Facet Biotech Corp (President & CEO, Director · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (President & CEO, Director · Oct 1, 2008 – Oct 1, 2008 · Past)
Director · Jun 30, 2020 – Feb 10, 2021 · Past
Daniel G. Welch
Other companies: Prothena Corporation plc (Chair of the Board · Since at least Feb 21, 2024); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Ultragenyx Pharmaceutical Inc. (Director · Since at least Apr 8, 2015); AveXis Inc (Director · Feb 10, 2016 – May 15, 2018 · Past); Intercept Pharmaceuticals Inc (Director · Nov 24, 2015 – May 28, 2020 · Past); Corium International Inc (Director · Apr 2, 2014 – Apr 2, 2014 · Past); Hyperion Therapeutics Inc (Director · Aug 23, 2012 – May 7, 2015 · Past); Seagen Inc (Director · Jun 13, 2007 – Dec 14, 2023 · Past); InterMune Inc (Chairman, CEO and President, Director · Mar 15, 2006 – Sep 29, 2014 · Past)
Director · Feb 10, 2021 – May 24, 2024 · Past
Graham Cooper
Other companies: Beam Therapeutics Inc. (Director · Since at least Feb 5, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Jan 27, 2022 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Assembly Biosciences, Inc. (See Remarks · Mar 8, 2018 – Mar 29, 2019 · Past); Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Jun 4, 2015 · Past); Receptos Inc (Chief Financial Officer · May 8, 2013 – Aug 27, 2015 · Past); Geron Corporation (EVP, Bus Dev & CFO · Jan 5, 2012 – May 17, 2012 · Past); Orexigen Therapeutics Inc (CFO and Treasurer · Apr 25, 2007 – Jan 18, 2011 · Past)
Director · Jun 30, 2020 – Feb 10, 2021 · Past
Shalini Sharp
Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2021 · Past); Sutro Biopharma, Inc. (Director · Nov 8, 2018 – Jun 6, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past); Agenus Inc. (Director · Oct 1, 2006 – Mar 2, 2018 · Past)
Director · Jun 30, 2020 – Feb 10, 2021 · Past
Oleg Nodelman
Other companies: Theravance Biopharma, Inc. (BSFS · Since at least Nov 5, 2026); Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Zymeworks Inc. (Director · Since at least Feb 17, 2025); AnaptysBio, Inc. (Member of the Nominating and Corporate Governance Committee · Since at least Apr 8, 2021); Panacea Acquisition II Corp (Director · Apr 6, 2020 – Apr 28, 2023 · Past); Prothena Corporation plc (Director · Dec 3, 2019 – Dec 3, 2019 · Past); Kindred Biosciences Inc (Director · Dec 11, 2013 – Sep 29, 2014 · Past)
Director · Jun 30, 2020 – Sep 19, 2023 · Past
David Hung
Other companies: NovoCure Limited (Director · Since at least May 31, 2018); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Jul 1, 2020 · Past); Establishment Labs Holdings Inc. (Director · Jul 18, 2018 – May 26, 2020 · Past); Sio Gene Therapies Inc (Principal Executive Officer, Director · Apr 7, 2017 – Dec 29, 2017 · Past); Acer Therapeutics Inc (Director · May 15, 2006 – Apr 5, 2011 · Past); Medivation Inc (President and CEO, Director · Apr 5, 2005 – Sep 28, 2016 · Past)
Founder, President and Chief Executive Officer · Since at least Feb 10, 2021
Robert Bazemore
Other companies: Akari Therapeutics PLC (Director · Since at least Sep 17, 2024); Ardelyx, Inc. (Director · Since at least Jun 2, 2016); Epizyme Inc (President & CEO, Director · Sep 10, 2015 – Mar 25, 2021 · Past); Synageva BioPharma Corp (Chief Operating Officer · Sep 22, 2014 – Jun 22, 2015 · Past)
Lead Independent Director, Board of Directors · Since at least Feb 10, 2021
Jennifer Fox
Other companies: Zenas BioPharma, Inc. (See Remarks · Since at least Sep 12, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); ProKidney Corp. (Director · Since at least Jul 11, 2022)
Chief Financial Officer · Feb 10, 2021 – Feb 28, 2023 · Past
All 33 people
PersonSeat
Scott Platshon
Other companies: Theravance Biopharma, Inc. (Executive Vice President and Chief Business Officer · Since at least Nov 4, 2026); Zymeworks Inc. (Executive Vice President and Chief Business Officer · Since at least Feb 22, 2024); Panacea Acquisition II Corp (Chief Operating Officer · Apr 6, 2021 – Apr 6, 2021 · Past)
Chief Operating Officer · Jun 30, 2020 – Jun 30, 2020 · Past
W. Anthony Vernon
Other companies: McCormick & Company, Incorporated (Director · Since at least Mar 15, 2018); NovoCure Limited (Director · Since at least May 31, 2017); Intersect ENT Inc (Director · Jun 5, 2018 – Jun 4, 2020 · Past)
Director · Since at least Feb 10, 2021
Xiangmin Cui
Other companies: Alpine Immune Sciences Inc (Director · Jan 18, 2019 – May 18, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); China Biologic Products Holdings Inc (Director · Feb 4, 2010 – Jan 1, 2011 · Past)
Director · Since at least Apr 9, 2024
Eisai Co
Other companies: Eisai Co., Ltd. (Ltd. Investor Relations Department · Since at least Mar 26, 2026); Biogen Inc. (Investor Relations Department · Since at least Jan 25, 2026)
Ltd. Investor Relations Department · Since at least Mar 26, 2026
Kerry Wentworth
Other companies: Flexion Therapeutics Inc (Chief Regulatory Officer · Dec 21, 2017 – Nov 19, 2021 · Past); Agenus Inc. (VP, Clinical, Reg & Qual · Jul 20, 2006 – Feb 26, 2014 · Past)
Chief Regulatory Officer · Since at least May 23, 2022
Kim D. Blickenstaff
Other companies: OPY Acquisition I Corp (Director · Oct 26, 2021 – Oct 26, 2021 · Past); Tandem Diabetes Care, Inc. (Director · Nov 10, 2020 – Nov 20, 2024 · Past)
Director · Since at least Feb 10, 2021
Michelle Doig
Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Omega Alpha SPAC (President, Director · Jan 6, 2021 – Jan 6, 2021 · Past)
Director · Feb 10, 2021 – Feb 10, 2021 · Past
Sergey Yurasov
Other companies: Black Diamond Therapeutics, Inc. (CHIEF MEDICAL OFFICER · Since at least Jun 10, 2022); Immune Design Corp (Sr. VP, Clinic. Devel. & CMO · Oct 1, 2016 – Apr 2, 2019 · Past)
Chief Medical Officer · Feb 10, 2021 – Feb 10, 2021 · Past
Thomas Templeman
Other companies: Centessa Pharmaceuticals PLC (Chief Technology Officer · May 27, 2021 – Mar 31, 2023 · Past); Medivation Inc (SVP, Pharmaceutical Operations · Sep 29, 2015 – Sep 29, 2015 · Past)
SVP, Pharmaceutical Ops · Feb 10, 2021 – Feb 10, 2021 · Past
Caroline Stout
Other companies: Panacea Acquisition II Corp (Chief Investment Officer · Apr 6, 2021 – Apr 6, 2021 · Past)
Chief Investment Officer · Jun 30, 2020 – Jun 30, 2020 · Past
Gary Hattersley
Other companies: Radius Health, Inc. (Chief Scientific Officer · May 17, 2011 – Dec 31, 2018 · Past)
Chief Scientific Officer · Since at least Feb 10, 2021
Sarah Marriott
Other companies: Panacea Acquisition II Corp (Secretary, Director · Apr 6, 2021 – Apr 6, 2021 · Past)
Secretary, Director · Jun 30, 2020 – Jun 30, 2020 · Past
Scott Perlen
Other companies: Panacea Acquisition II Corp (Chief Financial Officer · Apr 6, 2021 – Apr 6, 2021 · Past)
Chief Financial Officer · Jun 30, 2020 – Jun 30, 2020 · Past
Stacy Markel
Other companies: Rigel Pharmaceuticals, Inc. (EVP Human Resources · Mar 19, 2018 – Mar 20, 2019 · Past)
Chief People Officer · Since at least Feb 10, 2021
Colleen SjogrenChief Commercial Officer · Since at least Mar 27, 2024
David HanleyChief Technical Operations Officer · Since at least Jun 1, 2021
Dongfang LiuCHIEF MEDICAL OFFICER · Since at least Jul 15, 2022
Junyuan Jerry WangBoard of Directors · Since at least Apr 9, 2024
Min CuiBoard of Directors · Since at least Nov 5, 2026
Moses MakunjeSEE REMARKS · Since at least Nov 27, 2023
Philippe SauvageChief Financial Officer · Since at least Oct 7, 2024
Robert MashalBoard of Directors · Since at least Jan 8, 2024
Stephen DangChief Legal Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Nuvation Bio Inc.